| The candidate oncogene ZNF217 is frequently amplified in colon cancer. | colorectal, |
| Multiple roles of the candidate oncogene ZNF217 in ovarian epithelial neoplastic progression. | ovarian, |
| Silencing of ZNF217 gene influences the biological behavior of a human ovarian cancer cell line. | ovarian, |
| ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells. | breast, |
| ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells. | breast, |
| Identification of ZNF217, hnRNP-K, VEGF-A and IPO7 as targets for microRNAs that are downregulated in prostate carcinoma. | prostate, |
| downregulation of miR-24ZNF17 in prostate cancer (PCa) corresponds to an upregulation of ZNF217; ZNF217 could be identified as an oncogene because it is overexpressed in prostate cancer (PCa) and affects the growth of PCa cell lines | prostate, |
| Learning the local Bayesian network structure around the ZNF217 oncogene in breast tumours. | breast, |
| ZNF217 has an oncogenic role in colorectal cancer and is regulated by miR-203. | colorectal, |
| The report shows that the ZNF217 oncogene is a crucial mediator and indicator of bone metastasis from breast cancer. | breast, |
| Identification of genes directly regulated by the oncogene ZNF217 using chromatin immunoprecipitation (ChIP)-chip assays. | None |
| The ZNF217 oncogene is a candidate organizer of repressive histone modifiers. | None |
| The p15(ink4b) promoter is a target for the ZNF217 oncogene, the CoREST complex, and DNMT3A. | None |
| New insights into DNA recognition by zinc fingers revealed by structural analysis of the oncoprotein ZNF217. | None |